These data collectively elucidate a novel non-depleting mechanism by which BTKi mediates its effects on MS disease-implicated B-cell responses and reveals that modulating B-cell metabolism may be a viable therapeutic approach to target pro-inflammatory B cells. This evidence concerns the gene IBTK and myeloid sarcoma.